EC approves Roche's Hemlibra for people with severe haemophilia A without factor VIII
Roche announced the EC has approved Hemlibra® (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors. Hemlibra can be used in all age groups. March 14, 2019